The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 2, 2005, Pages 868-875

  Shoemaker, Jennifer L ^a   Joseph, Biny K ^a   Ruckle, Michael B ^a   Mayeux, Philip R ^a   Prather, Paul L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ADENYLATE CYCLASE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; GUANINE NUCLEOTIDE BINDING PROTEIN; NOLADIN ETHER; PERTUSSIS TOXIN; UNCLASSIFIED DRUG;

AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL STRAIN HL 60; CHO CELL; DESENSITIZATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM;

ADENYLATE CYCLASE; ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; BIOTRANSFORMATION; CHO CELLS; CRICETINAE; CYCLIC AMP; CYCLOHEXANOLS; DOWN-REGULATION; ENZYME INHIBITORS; GLYCERIDES; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HL-60 CELLS; HUMANS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; TRANSFECTION;

EID: 22944467514     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.085282     Document Type: Article

References (37)

1. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, and Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23:11136-11141.
2. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, Calandra B, Le Fur G, and Casellas P (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237:704-711.
3. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, and Sim-Selley LJ (1999) Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73:2447-2459.
4. Brotchie JM (2003) CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 3:54-61.
5. Calignano A, La Rana G, Giuffrida A, and Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature (Lond) 394:277-281.
6. Cheng Y and PrusoffW(1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (i50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Conti S, Costa B, Colleoni M, Parolaro D, and Giagnoni G (2002) Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135:181-187.
8. Cravatt B and Lichtman A (2004) The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61:149-160.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash DC) 258:1946-1949.
10. Di Marzo V, Bifulco M, and De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784.
11. Di Marzo V and Fontana A (1995) Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot Essent Fatty Acids 53:1-11.
12. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, and Di Marzo V (2002) Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 513:294-298.
13. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
14. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, and Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665.
15. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
16. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634.
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
18. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, et al. (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100:10529-10533.
19. Ishac E, Jiang L, Lake K, Varga K, Abood M, and Kunos G (1996) Inhibition of exocytotic noradrenaline release by presynaptic CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023-2028.
20. Iversen L and Chapman V (2002) Cannabinoids: a real prospect for pain relief. Curr Opin Pharmacol 2:50-55.
21. Kenakin T (1977) Molecular Pharmacology: A Short Course, Blackwell Science, Cambridge, MA.
22. Klein T, Newton C, Larsen K, Lu L, Perkins I, Liang N, and Friedman H (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496.
23. Matsuda L, Lolait S, Brownstein M, Young A, and Bonner T (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
24. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
25. Munro S, Thomas K, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
26. Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, and Sugiura T (2003) Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem 85:1374-1381.
27. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020-1024.
28. Prather PL, Martin NA, Breivogel CS, and Childers SR (2000a) Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol Pharmacol 57:1000-1010.
29. Prather PL, Song L, Piros ET, Law PY, and Hales TG (2000b) Delta-opioid receptors are more efficiently coupled to adenylyl cyclase than to L-type Ca(2+) channels in transfected rat pituitary cells. J Pharmacol Exp Ther 295:552-562.
30. Racz I, Bilkei-Gorzo A, Toth Z, Michel K, Palkovits M, and Zimmer A (2003) A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 23:2453-2458.
31. Ravinet T, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand J, and Soubrie P (2002) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet induced obese mice. Am J Physiol 284:345-353.
32. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
33. Ross R, Brockie H, Stevenson L, Murphy V, Templeton F, Makriyannis A, and Pertwee R (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126:665-672.
34. Scott D, Wright C, and Angus J (2004) Evidence that CB1 and CB2 cannabinoid receptors mediate antinoception in neuropathic pain in the rat. Pain 109:124-131.
35. Steffens M, Zentner J, Honegger J, and Feuerstein T (2005) Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB(1) receptor. Biochem Pharmacol 69:169-178.
36. Sugiura T, Oka S, Gokoh M, Kishimoto S, and Waku K (2004) New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. J Pharmacol Sci 96:367-375.
37. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, and Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405.